Anzeige
Meldung des Tages: Unter dem Radar, voll finanziert: Beginnt jetzt der nächste Gold-Run?

Sarepta Therapeutics News

Aktie
WKN:  A1J1BH ISIN:  US8036071004 US-Symbol:  SRPT Branche:  Biotechnologie Land:  USA
18,24 €
+0,16 €
+0,88%
13.04.26
Depot/Watchlist
Marktkapitalisierung *
1,97 Mrd. €
Streubesitz
9,99%
KGV
56,03
Index-Zuordnung
Nasdaq Composite Index

Sarepta Therapeutics News

28.11.25 wallstreetONLINE Redaktion
Hände weg von diesen Aktien!: Beliebte Strategie kann Verkaufswelle bei DIESEN Aktien auslösen
Bei der traditionellen Depot-​Säuberung zum Jahresende verkaufen Anleger massenhaft Verlierer-​Aktien, um Steuern zu sparen. Aktien wie Enphase, Lucid und Trump Media ...
20.11.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT PR Newswire
21.10.25 - PR Newswire
Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF
Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF PR Newswire
24.09.25 - PR Newswire
Kuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law Firm PR Newswire
15.09.25 - PR Newswire
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth PR Newswire
26.08.25 - PR Newswire
Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600
Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 PR Newswire
25.08.25 - PR Newswire
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire
25.08.25 - PR Newswire
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT PR Newswire
25.08.25 - PR Newswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
22.08.25 - PR Newswire
SRPT Deadline: SRPT Investors with Losses in Excess of $100K Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
SRPT Deadline: SRPT Investors with Losses in Excess of $100K Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
22.08.25 - PR Newswire
INVESTOR DEADLINE MONDAY: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT
INVESTOR DEADLINE MONDAY: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT PR Newswire
22.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT ...
22.08.25 - PR Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics PR Newswire
21.08.25 - PR Newswire
INVESTOR DEADLINE AUGUST 25: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT
INVESTOR DEADLINE AUGUST 25: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT PR Newswire
21.08.25 - PR Newswire
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join - Contact The Gross Law Firm
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire
21.08.25 - PR Newswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
21.08.25 - PR Newswire
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT PR Newswire
19.08.25 - PR Newswire
Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More PR Newswire
18.08.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders PR Newswire
18.08.25 - PR Newswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire

Newssuche

Videos

newspaper
07.04.26 +4,00%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »